SCHEMBL9923896

SCHEMBL9923896

COC(=O)c1ccc(S(=O)(=O)N(C(=O)OC(C)(C)C)c2nc3c(C)cccn3c2C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
CYP2C9 P11712 3/20 0.35
MAPT P10636 4/20 0.34
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
GAA P10253 1/20 0.34
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 2/20 0.33
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9923886 0.86 ALDH1A1 (0.41) FBP1SMN1; SMN2MAPTKMT2AGAA
SCHEMBL9893395 0.79 KMT2A (0.42) FBP1SMN1; SMN2CYP2C9MAPTCYP1A2
SCHEMBL9893216 0.79 PSEN1 (0.37) FBP1SMN1; SMN2CYP2C9MAPTALDH1A1
SCHEMBL9923898 0.78 ALDH1A1 (0.40) FBP1SMN1; SMN2MAPTGAAALDH1A1
SCHEMBL9923894 0.75 TRPM8 (0.56)
SCHEMBL15631066 0.74 KMT2A (0.39) SMN1; SMN2CYP2C9CYP1A2CYP2C19KMT2A
SCHEMBL9893330 0.73 MAPT (0.47) FBP1SMN1; SMN2CYP2C9MAPTMEN1
SCHEMBL9923991 0.69 ALDH1A1 (0.40) SMN1; SMN2MAPTMEN1KMT2AALDH1A1
SCHEMBL9923890 0.67 TRPM8 (0.65)
SCHEMBL9905554 0.66 TRPM8 (0.64)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067935-B2 Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2015-06-30 US disclosed
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-03-27 US disclosed
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2012-06-14 US disclosed
WO-2012078994-A1 IMIDAZO [1, 2-A] PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 FBP1 1589/4885SMN1; SMN2 442/4885CYP2C9 2887/4885
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 FBP1 1589/4885SMN1; SMN2 442/4885CYP2C9 2887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.